# Jasper Therapeutics, Inc.: overview JSPR · Nasdaq · CIK 1788028 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/jspr.md) · [Financials](/companies/jspr/financials.md) · [Filings](/companies/jspr/filings.md) · [Insiders](/companies/jspr/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.24)](/filings/0001213900-25-107884.md) | not reported | [(1.41)](/filings/0001213900-26-056595.md) | [(1.74)](/filings/0001213900-26-089592.md) | [(1.13)](/filings/0001213900-25-107884.md) | not reported | [(0.04)](/filings/0001213900-26-056595.md) | [(0.10)](/filings/0001213900-26-089592.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.69)](/filings/0001213900-23-018542.md) | [(10.33)](/filings/0001213900-24-020114.md) | [(6.18)](/filings/0001213900-25-018384.md) | [(4.89)](/filings/0001213900-26-036426.md) | [(3.95)](/filings/0001213900-26-036426.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/jspr/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2024-02-08 | [Carlyle Group Inc.](/insiders/1527166.md) | Former 10% Owner | Purchase (P) | 190,000 | $12.95 | $2.5m | [Form 4](/filings/0000950170-24-014017.md) | | 2023-01-27 | [Carlyle Group Inc.](/insiders/1527166.md) | 10% owner | Purchase (P) | 3,133,333 | $1.50 | $4.7m | [Form 4](/filings/0000899243-23-003059.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Velan Capital Investment Management LP](/funds/1848809.md) | 2026-06-30 | $1.1m | 2,668,395 | | Unchanged | | [ACORN CAPITAL ADVISORS, LLC](/funds/2054410.md) | 2026-06-30 | $604.0k | 1,438,159 | | Added +26,667 | | [KINGDON CAPITAL MANAGEMENT, L.L.C.](/funds/1000097.md) | 2026-06-30 | $569.2k | 1,352,106 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $493.4k | 1,172,021 | | Reduced −576 | | [Rock Springs Capital Management LP](/funds/1595725.md) | 2026-06-30 | $463.4k | 1,100,726 | | Unchanged | | [Carlyle Group Inc.](/funds/1527166.md) | 2026-06-30 | $448.9k | 1,066,189 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $205.0k | 486,933 | | Reduced −1,130,598 | | [Lion Point Capital, LP](/funds/1643354.md) | 2026-06-30 | $195.8k | 465,000 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $111.1k | 263,808 | | Reduced −53,869 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $100.2k | 237,900 | | Added +60,400 | ## Recent filings [All 463 filings](/companies/jspr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 13:33 ET | [DEF 14A](/filings/0001213900-26-110751.md) | Proxy statement, period 2026-11-13 | 0001213900-26-110751 | | 2026-10-15 | 12:00 ET | [8-K](/filings/0001213900-26-109587.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-109587 | | 2026-10-07 | 12:05 ET | [8-K](/filings/0001213900-26-107402.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-107402 | | 2026-10-05 | 12:00 ET | [8-K](/filings/0001213900-26-106651.md) | 5.07 Shareholder vote results | 0001213900-26-106651 | | 2026-10-05 | 22:54 ET | [8-K/A](/filings/0001213900-26-106574.md) | 9.01 Financial statements and exhibits | 0001213900-26-106574 | | 2026-10-01 | 21:29 ET | [8-K/A](/filings/0001213900-26-105924.md) | 9.01 Financial statements and exhibits | 0001213900-26-105924 | | 2026-09-28 | 20:44 ET | [8-K](/filings/0001213900-26-104101.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-104101 | | 2026-09-04 | 19:08 ET | [DEF 14A](/filings/0001213900-26-097572.md) | Proxy statement, period 2026-09-30 | 0001213900-26-097572 | | 2026-08-26 | 20:15 ET | [8-K](/filings/0001213900-26-093979.md) | 1.01 Entry into a material agreement | 0001213900-26-093979 | | 2026-08-14 | 20:07 ET | [8-K](/filings/0001213900-26-090055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090055 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036426.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1788028 - Tickers: JSPR - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.